Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FATE NYSE:IKT OTCMKTS:PVCT NASDAQ:PYXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFATEFate Therapeutics$0.96-5.6%$1.09$0.66▼$4.20$117.64M2.211.35 million shs1.44 million shsIKTInhibikase Therapeutics$1.56-7.1%$1.76$1.12▼$4.20$116.25M0.91183,507 shs78,545 shsPVCTProvectus Biopharmaceuticals$0.07+1.3%$0.08$0.07▼$0.15$28.62M0.53170,188 shs234,091 shsPYXSPyxis Oncology$1.82-2.2%$1.28$0.83▼$5.39$115.35M1.14775,544 shs723,147 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFATEFate Therapeutics-5.58%-4.64%-14.77%-24.46%-75.18%IKTInhibikase Therapeutics-7.14%-6.59%-8.77%-16.13%+18.18%PVCTProvectus Biopharmaceuticals+1.32%-6.38%-20.69%-6.38%-34.84%PYXSPyxis Oncology-2.15%-4.71%+70.09%+51.67%-50.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFATEFate Therapeutics$0.96-5.6%$1.09$0.66▼$4.20$117.64M2.211.35 million shs1.44 million shsIKTInhibikase Therapeutics$1.56-7.1%$1.76$1.12▼$4.20$116.25M0.91183,507 shs78,545 shsPVCTProvectus Biopharmaceuticals$0.07+1.3%$0.08$0.07▼$0.15$28.62M0.53170,188 shs234,091 shsPYXSPyxis Oncology$1.82-2.2%$1.28$0.83▼$5.39$115.35M1.14775,544 shs723,147 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFATEFate Therapeutics-5.58%-4.64%-14.77%-24.46%-75.18%IKTInhibikase Therapeutics-7.14%-6.59%-8.77%-16.13%+18.18%PVCTProvectus Biopharmaceuticals+1.32%-6.38%-20.69%-6.38%-34.84%PYXSPyxis Oncology-2.15%-4.71%+70.09%+51.67%-50.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFATEFate Therapeutics 2.14Hold$3.30242.64% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50316.67% UpsidePVCTProvectus Biopharmaceuticals 0.00N/AN/AN/APYXSPyxis Oncology 2.67Moderate Buy$7.75325.82% UpsideCurrent Analyst Ratings BreakdownLatest PVCT, PYXS, FATE, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025PYXSPyxis OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.009/3/2025PYXSPyxis OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.008/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/18/2025PYXSPyxis OncologyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/13/2025FATEFate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$4.00 ➝ $2.50(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFATEFate Therapeutics$13.63M8.15N/AN/A$2.80 per share0.34IKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/APVCTProvectus Biopharmaceuticals$620K46.77N/AN/A($0.01) per share-6.90PYXSPyxis Oncology$16.15M6.99N/AN/A$2.03 per share0.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFATEFate Therapeutics-$186.26M-$1.45N/AN/AN/A-2,025.05%-50.95%-36.76%11/11/2025 (Estimated)IKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/APVCTProvectus Biopharmaceuticals-$4.76MN/A0.00∞N/A-1,374.19%N/A-792.87%11/10/2025 (Estimated)PYXSPyxis Oncology-$77.33M-$1.60N/AN/AN/AN/A-68.56%-52.14%11/11/2025 (Estimated)Latest PVCT, PYXS, FATE, and IKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PYXSPyxis Oncology-$0.36-$0.30+$0.06-$0.30N/A$2.82 million8/12/2025Q2 2025FATEFate Therapeutics-$0.35-$0.29+$0.06-$0.29$1.16 million$1.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFATEFate TherapeuticsN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/APVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFATEFate TherapeuticsN/A8.048.04IKTInhibikase TherapeuticsN/A0.850.85PVCTProvectus BiopharmaceuticalsN/A0.090.09PYXSPyxis OncologyN/A5.655.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFATEFate Therapeutics97.54%IKTInhibikase Therapeutics3.81%PVCTProvectus Biopharmaceuticals0.05%PYXSPyxis Oncology39.09%Insider OwnershipCompanyInsider OwnershipFATEFate Therapeutics5.51%IKTInhibikase Therapeutics7.30%PVCTProvectus Biopharmaceuticals14.70%PYXSPyxis Oncology10.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFATEFate Therapeutics550115.33 million108.98 millionOptionableIKTInhibikase Therapeutics674.52 million66.18 millionNot OptionablePVCTProvectus Biopharmaceuticals4420.28 million358.50 millionNot OptionablePYXSPyxis Oncology6062.02 million55.44 millionOptionablePVCT, PYXS, FATE, and IKT HeadlinesRecent News About These CompaniesPyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade)September 12 at 4:47 PM | seekingalpha.comPyxis Oncology, Inc. $PYXS Holdings Lowered by American Century Companies Inc.September 9, 2025 | marketbeat.comInvesting in Oncology: 3 Cancer Stocks With Promising PipelinesSeptember 8, 2025 | zacks.comPyxis Oncology (NASDAQ:PYXS) Raised to Strong-Buy at GuggenheimSeptember 8, 2025 | marketbeat.comGuggenheim Initiates Coverage of Pyxis Oncology (PYXS) with Buy RecommendationSeptember 5, 2025 | msn.comPyxis Oncology initiated with a Buy at GuggenheimSeptember 3, 2025 | msn.comAnalysts Set Pyxis Oncology, Inc. (NASDAQ:PYXS) Price Target at $8.67September 2, 2025 | americanbankingnews.comPyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 1, 2025 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street ZenAugust 26, 2025 | marketbeat.comHC Wainwright Predicts Increased Earnings for Pyxis OncologyAugust 23, 2025 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Raised to Hold at Zacks ResearchAugust 22, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS)August 21, 2025 | marketbeat.comPyxis Oncology to Participate in September Investor and Industry ConferencesAugust 21, 2025 | globenewswire.comWilliam Blair Forecasts Pyxis Oncology Q1 EarningsAugust 19, 2025 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPSAugust 18, 2025 | marketbeat.comPyxis Oncology reports Q2 EPS (30c), consensus (35c)August 14, 2025 | msn.comPyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comWe Think Pyxis Oncology (NASDAQ:PYXS) Needs To Drive Business Growth CarefullyAugust 2, 2025 | finance.yahoo.comPyxis Oncology Inc News (PYXS) - Investing.comJuly 8, 2025 | investing.comPyxis Oncology Chief Financial, Operating Officer Pamela Connealy Retires >PYXSJuly 3, 2025 | marketwatch.comPyxis Oncology Appoints New Principal Financial OfficerJuly 3, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePVCT, PYXS, FATE, and IKT Company DescriptionsFate Therapeutics NASDAQ:FATE$0.96 -0.06 (-5.58%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.00 +0.04 (+4.04%) As of 09/12/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Inhibikase Therapeutics NYSE:IKT$1.56 -0.12 (-7.14%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.57 +0.01 (+0.71%) As of 09/12/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Provectus Biopharmaceuticals OTCMKTS:PVCT$0.07 +0.00 (+1.32%) As of 09/12/2025 03:56 PM EasternProvectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.Pyxis Oncology NASDAQ:PYXS$1.82 -0.04 (-2.15%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.84 +0.02 (+1.10%) As of 09/12/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
